Prediction and treatment of immunotherapeutic toxicity
AssigneeBoard of Regents, The University of Texas System
InventorsEdward WAKELAND, David E. GERBER, Quan LI, Shaheen KHAN, Saad KHAN, Yang XIE, Jason Y. Park, Farjana FATTAH, Xin LUO
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy—induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
Claims35
A method of predicting/diagnosing immunotherapeutic toxicity in a human subject comprising:
- (a) providing a chemokine- and/or cytokine-containing sample from said subject;
- (b) assessing one or more chemokine- and or cytokine levels in said sample;
- and
- (c) predicting/diagnosing immunotherapy toxicity in said subject when the level of one or more chemokine and/or cytokine is increased from than populational average and predicting lack of immunotherapy toxicity in said subject when the level of one or more chemokine and/or cytokine is below populational average.
5-6. (canceled)
(canceled)
(canceled)
13-14. (canceled)
(canceled)
19-20. (canceled)
A method of treating a human subject with cancer comprising:
- (a) providing a chemokine- and or cytokine-containing sample from said subject;
- (b) assessing one or more chemokine and or cytokine levels in said sample;
- and
- (c) treating said subject with
- (i) a cancer immunotherapy when a chemokine- and or cytokine level is found to be below populational average;
- (ii) a non-immunotherapy cancer treatment when a chemokine- and or cytokine level is found to be above populational average;
- or
- (iii) a cancer immunotherapy and an immunotherapy toxicity mitigating therapy when a chemokine- and or cytokine level is found to be above populational average.
22-37. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of determining whether a subject has recovered from immunotherapy toxicity comprising:
- (a) providing a first chemokine- and/or cytokine-containing sample from said subject following immunotherapy and the development of immunotherapy toxicity;
- (b) assessing chemokine and/or cytokine levels in said first antibody-containing sample;
- (c) providing a second chemokine- and/or cytokine-containing sample from said subject after immunotherapy toxicity has subsided;
- (d) assessing chemokine and/or cytokine levels in said second antibody-containing sample;
- and
- (e) classifying said subject as suitable for further immunotherapy when one or more chemokine and/or cytokine levels have dropped by at least 50% in said second chemokine- and/or cytokine-containing sample as compared to said first chemokine- and/or cytokine-containing sample.
53-83. (canceled)
Dependencies are inferred from the claim text.